Table 2.
Association of Baseline CRP Category with ESRD, Doubling of Scr, Composite of ESRD or Doubling of Scr, Composite of ESRD or Death, CV Composite, and Death alone
| Model: Events/Total | HR (95% CI) | P for trend |
|
|---|---|---|---|
| CRP >3.0–<6.9 mg/L | CRP ≥6.9 mg/L | ||
| Development of ESRD | |||
| Unadjusted: 668/4,038 | 1.21 (1.01 – 1.46) | 1.37 (1.14 – 1.64) | 0.001 |
| Adjusted: 598/3,642 | 1.08 (0.88 – 1.33) | 1.32 (1.07 – 1.63) | 0.01 |
| Competing Risk: 598/3,642 | 1.01 (0.81–1.25) | 1.23 (0.99–1.53) | 0.09 |
| Doubling of Scr | |||
| Unadjusted: 428/3,654 | 0.96 (0.76 – 1.22) | 1.06 (0.84 – 1.35) | 0.7 |
| Adjusted: 367/3,305 | 0.90 (0.69 – 1.18) | 0.94 (0.71 – 1.25) | 0.6 |
| Competing Risk: 367/3,305 | 0.86 (0.65–1.14) | 0.93 (0.69–1.25) | 0.5 |
| Composite of ESRD/Scr Doubling | |||
| Unadjusted: 871/4,038 | 1.16 (0.99 – 1.37) | 1.28 (1.09 – 1.51) | 0.002 |
| Adjusted: 769/3,642 | 1.05 (0.87 – 1.26) | 1.17 (0.97 – 1.42) | 0.1 |
| Competing Risk: 769/3,642 | 0.99 (0.82–1.20) | 1.12 (0.92–1.36) | 0.3 |
| Death or ESRD | |||
| Unadjusted: n=1,270/4,038 | 1.21 (1.05 – 1.39) | 1.57 (1.38 – 1.79) | <0.001 |
| Adjusted: n=1,139/3,642 | 1.11 (0.96 – 1.29) | 1.41 (1.21 – 1.64) | <0.001 |
| CV Composite Outcome* | |||
| Unadjusted: n=1,234/4,038 | 1.26 (1.09 – 1.45) | 1.77 (1.55 – 2.02) | <0.001 |
| Adjusted: n=1,111/3,642) | 1.16 (0.99 – 1.35) | 1.55 (1.34 – 1.81) | <0.001 |
| Association With Death From Any Cause | |||
| Unadjusted: n=807/4,038 | 1.20 (1.00 – 1.43) | 1.85 (1.57 – 2.16) | <0.001 |
| Adjusted: n=734/3,642 | 1.15 (0.95 – 1.39) | 1.59 (1.32 – 1.91) | <0.001 |
Note: CRP ≤ 3.0 mg/L was reference category for all. The multivariable models were adjusted for age, gender, race, estimated glomerular filtration rate, log-transformed urine protein-creatinine ratio, history of acute kidney injury, duration of type 2 diabetes mellitus, glycated hemoglobin, retinopathy, insulin use, body mass index, hemoglobin, serum albumin, coronary artery disease, cerebrovascular disease, peripheral arterial disease, heart failure, systolic blood pressure, low-density lipoprotein cholesterol concentration, statin therapy, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy, smoking status, ferritin, transferrin saturation, iron therapy and randomized treatment assignment. Multivariable adjusted competing risk models were fit, with death as the competing outcome, for the end points of ESRD, doubling of Scr and the composite of ESRD/doubling of Scr.
CI, confidence intervak; CRP, C-reactive protein; CV, cardiovacular; ESRD, end-stage renal disease; HR, hazard ratio; Scr, serum creatinine
CV composite included death from any cause, nonfatal MI, stroke, heart failure or hospitalization for myocardial ischemia